Gastrointestinal and hematologic toxicities have been observed in other studies with CDK9 inhibitors and CK1a degrading therapies (e.g. lenalidomide).(23, 25, 34) Notably, none of the patients receiving BTX-A51 experienced tumor lysis syndrome. This evidence concerns the gene CSNK1A1 and Tumor Lysis Syndrome.